

Amendments to the Claims


This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (previously presented) A method of inhibiting thrombin-induced cell activation mediated by cleavage of a thrombin receptor on said cells comprising administering to an individual in need of such treatment an effective amount of a compound selected from the group consisting of:

- (a) Arg-Pro-Pro;
- (b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);
- (c) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(d)



2. (canceled).

3. (canceled).

4. (canceled).

5. (canceled).

6. (canceled).

7. (canceled).

8. (canceled).

9. (canceled).

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)


14. (previously presented) A method for preventing thrombin-induced platelet aggregation mediated by cleavage of a thrombin receptor on said platelets comprising administering to an individual in need of such treatment an effective amount of a compound selected from the group consisting of:

(a) Arg-Pro-Pro;

(b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);

(c) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(d)



15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (canceled).

20. (canceled).

21. (canceled)

22. (canceled).


23. (canceled)

24. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6).

25. (previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having a formula selected from the group consisting of:

- (a) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(b)



26. (canceled).


27. (canceled).

28. (canceled)


29. (previously presented) The method according to claim 1 wherein the compound is Arg-Pro-Pro.

30. (previously presented) The method according to claim 1 wherein the compound is Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6).

31. (previously presented) The method according to claim 1 wherein the compound is




32. (previously presented) The method according to claim 1 wherein the compound is



33. (previously presented) The method according to claim 14 wherein the compound is Arg-Pro-Pro.

34. (previously presented) The method according to claim 14 wherein the compound is Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6).

35. (currently amended) The method according to claim 14 wherein the compound is:



36. (previously presented) The method according to claim 14 wherein the compound is:

